Micron-size Palmitoylethanolamide for long-term pain relief

Summaries 1 min 476

Font Size

Created On: 09/09/2024

Palmitoylethanolamide is effective for chronic pain, but the optimal duration of its micron-size treatment is undefined.

See All

Key take away

Micron-size Palmitoylethanolamide for 60+ days significantly reduces chronic pain, an indispensable option for managing chronic pain.

Background

Palmitoylethanolamide is effective for chronic pain, but the optimal duration of its micron-size treatment is undefined. This systematic review and meta-analysis assessed the potential benefits of extended (>60 days) versus shorter-duration Palmitoylethanolamide therapy in relieving chronic pain.

Method

A comprehensive literature search was conducted across scientific databases to recognise clinical trials fulfilling criteria where micron-size Palmitoylethanolamide was administered for at least 60 days. The Visual Analogue Scale (VAS) or Numeric Rating Scale (NRS) were used to assess pain. Nine studies involving 742 patients met the inclusion criteria. A meta-analysis was performed to compare pain intensity reductions between treatment durations.

Result

The meta-analysis demonstrated a considerable reduction in pain intensity with 60 days of micron-size Palmitoylethanolamide supplementation compared to 30 days (1.36 points reduction, p < 0.01). Secondary analysis revealed a 2.08-point decrease in NRS/VAS scores during the first month, equating to a 35.1% reduction in pain intensity. This improvement continued with an additional 35.4% decrease in the second month of treatment (Table 1):

Conclusion

Extended supplementation of micron-size Palmitoylethanolamide provides a significant advantage over shorter treatments, particularly for patients experiencing incomplete pain management.